Charles River Labs officer granted 2,926 shares; vests 2026–2027

Rhea-AI Filing Summary

Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.

The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Knell Michael Gunnar

Role CSVP, CAO, Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,926	$170.88	$500K

Holdings After Transaction: Common Stock — 13,460 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knell Michael Gunnar

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSVP, CAO, Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2025		A		2,926(1)	A	$170.88	13,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 50% of the unvested restricted stock units vest on November 6, 2026, with the remaining 50% vesting on November 6, 2027.

	/s/ Michael G. Knell	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CRL’s Interim CFO report on Form 4?

An acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (code A).

How many CRL shares does the reporting person now own?

Beneficial ownership stands at 13,460 shares, held directly.

What is the vesting schedule for the CRL RSUs?

50% vest on November 6, 2026 and 50% vest on November 6, 2027.

Who is the reporting person for CRL?

Michael G. Knell, CRL’s CSVP, CAO, Interim CFO.

What does transaction code A indicate in the CRL filing?

Code A indicates an award/grant, consistent with the reported RSUs.

What company and ticker does the Form 4 relate to?

Charles River Laboratories International, Inc. (CRL).